Study on efficacy of multiplex PCR assay (rapid test) in diagnosis and treatment of bacterial pneumonia in patients with COVID-19

Abstract

Introduction: an inflammatory condition of the tissues within one or maybe both lungs which is most typically, but sometimes not, triggered by infection. Bacterial Pneumonia comes in a variety of forms. COVID-19 primarily is largely a respiratory illness, including symptomatology ranging from a cold or flu sickness to acute respiratory distress syndrome (ARDS). COVID-19 infestation will activate both innate and adaptive immune responses, along with localised antibody production, macrophage and monocyte migration, cytokine production, as well as priming of adaptive T- and B-cells during an attempt to settle underpinning inflammatory response. Secondary bacterial pneumonia has become one of the potential aspects related to COVID-19. Secondary bacterial infections have been found to be strongly related to higher risks and mortality in COVID-19 individuals throughout recent research. Quantitative PCR assays may be used to determine overall patterns of viral growth, evaluate the effectiveness of therapy, as well as distinguish between latent and active transmission among viruses that survive in designated cell types, especially in addition to evaluating infection rate at such a given instant of time.